387 related articles for article (PubMed ID: 31949048)
1. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
[TBL] [Abstract][Full Text] [Related]
2. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG
J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977
[TBL] [Abstract][Full Text] [Related]
3. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
Galvan AM; Chorba JS
J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
[TBL] [Abstract][Full Text] [Related]
4. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
[TBL] [Abstract][Full Text] [Related]
5. Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding.
Deng SJ; Alabi A; Gu HM; Adijiang A; Qin S; Zhang DW
J Lipid Res; 2019 Mar; 60(3):516-527. PubMed ID: 30617148
[TBL] [Abstract][Full Text] [Related]
6. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
7. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
Lu X
Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
[TBL] [Abstract][Full Text] [Related]
8. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
10. Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor.
Holla ØL; Laerdahl JK; Strøm TB; Tveten K; Cameron J; Berge KE; Leren TP
Biochem Biophys Res Commun; 2011 Mar; 406(2):234-8. PubMed ID: 21324305
[TBL] [Abstract][Full Text] [Related]
11. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding.
Sarkar SK; Matyas A; Asikhia I; Hu Z; Golder M; Beehler K; Kosenko T; Lagace TA
Front Physiol; 2022; 13():960272. PubMed ID: 36187800
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Helical Segment within the Intrinsically Disordered Region of the PCSK9 Prodomain.
Ultsch M; Li W; Eigenbrot C; Di Lello P; Lipari MT; Gerhardy S; AhYoung AP; Quinn J; Franke Y; Chen Y; Kong Beltran M; Peterson A; Kirchhofer D
J Mol Biol; 2019 Mar; 431(5):885-903. PubMed ID: 30653992
[TBL] [Abstract][Full Text] [Related]
14. Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor.
Garvie CW; Fraley CV; Elowe NH; Culyba EK; Lemke CT; Hubbard BK; Kaushik VK; Daniels DS
Protein Sci; 2016 Nov; 25(11):2018-2027. PubMed ID: 27534510
[TBL] [Abstract][Full Text] [Related]
15. The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9.
Sánchez-Hernández RM; Di Taranto MD; Benito-Vicente A; Uribe KB; Lamiquiz-Moneo I; Larrea-Sebal A; Jebari S; Galicia-Garcia U; Nóvoa FJ; Boronat M; Wägner AM; Civeira F; Martín C; Fortunato G
Atherosclerosis; 2019 Oct; 289():162-172. PubMed ID: 31518966
[TBL] [Abstract][Full Text] [Related]
16. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
17. In Silico Insights into Protein-protein Interaction Disruptive Mutations in the PCSK9-LDLR complex.
Martin WR; Lightstone FC; Cheng F
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106405
[TBL] [Abstract][Full Text] [Related]
18. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
19. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
20. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
